Oxford Nanopore Technologies /£ONT

08:00
10:10
12:15
14:25
16:30
1D1W1MYTD1Y5YMAX

About Oxford Nanopore Technologies

Oxford Nanopore Technologies plc, trading under the ticker ONT, operates in the biotechnology sector, focusing on the development of nanopore technology for DNA and RNA sequencing. Founded in 2005 and publicly listed, the company's innovative technology facilitates real-time, scalable, and accessible biological research, with applications ranging from healthcare to environmental science. Based in the UK, Oxford Nanopore has revolutionized the approach to molecular analysis by providing a direct and electric characterization of single molecules.

Ticker

£ONT
Sector

Primary listing

LSE

Employees

1,325

ONT Metrics

BasicAdvanced
£1.3B
-
-£0.15
0.83
-

What the Analysts think about ONT

Analyst ratings (Buy, Hold, Sell) for Oxford Nanopore Technologies stock.

Bulls say / Bears say

The stock bounced back 75% over the last year, supported by institutional investors such as Larry Ellison’s EIT and Novo Holdings, indicating renewed confidence in the company’s future (FT)
Strategic moves into clinical and pharmaceutical markets are opening up new revenue channels beyond academic research, bolstering long-term growth prospects (FT)
Reported takeover interest from life sciences giants like Thermo Fisher Scientific and Danaher highlights Oxford Nanopore’s nanopore sequencing platform as a highly valuable strategic asset (FT)
Shares have dropped nearly 70% from their peak since the 2021 IPO, highlighting ongoing market volatility and lingering investor skepticism (FT)
Weaker demand for sequencing tools and reduced investment in biotech and research sectors are holding back core revenue growth (FT)
CEO Gordon Sanghera’s plan to step down by the end of 2026 could increase leadership and strategic uncertainty at a crucial time for the company (FT)
Data summarised monthly by Lightyear AI. Last updated on 3 Nov 2025.

ONT Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

ONT Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.

Buy £ONT

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs